586.78MMarket Cap-5.25P/E (TTM)
8.750High8.180Low4.90MVolume8.310Open8.180Pre Close41.07MTurnover6.94%Turnover RatioLossP/E (Static)71.12MShares14.84052wk High4.40P/B582.43MFloat Cap5.27552wk Low--Dividend TTM70.60MShs Float978.000Historical High--Div YieldTTM6.97%Amplitude-1731.000Historical Low8.382Avg Price1Lot Size
Altimmune Stock Forum
$Altimmune (ALT.US)$
Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024
Altimmune (Nasdaq: ALT) presented new data from its 12-week Phase 1b trial of pemvidutide in MASLD patients at The Liver Meeting®.
The study demonstrated that weekly subcutaneous doses of pemvidutide significantly reduced inflammatory lipids and showed promising effects on cardiovascul...
Larger Image: tradingview.com...
$Altimmune (ALT.US)$
Will a partner be announced or are the rumours true a buy out is eminent..!
No comment yet